VIVEbiotech celebrates 10 years of innovation in lentiviral vector manufacturing
)
Over the years, we have reached several key milestones:
- 53 international partners rely on our lentiviral vectors for their advanced therapies.
- Our team has expanded to 140 highly skilled professionals, working at the forefront of gene therapy manufacturing.
- We were recently honored as “CMO/CDMO of the Year” at the Advanced Therapies Awards in Dallas this past January.
Adding to this momentum, VIVEbiotech has secured a major investment milestone that will fuel our continued growth and expansion. Read more
Looking ahead: a future built on excellence
At VIVEbiotech, we are more than a lentiviral vector manufacturing CDMO—we are virology experts supporting our partners from the earliest stages of development. Our mission remains clear: to contribute to the success of gene therapy programs that are transforming lives.
As we celebrate this milestone, we extend our heartfelt gratitude to our clients, partners, and our exceptional team. Thank you for being part of our journey—here’s to the next decade of breakthroughs!